PRODUCTION OF NONTOXIC RAW MATERIALS AND FINISHED PRODUCTS TESTED BY MEANS OF AN INNOVATIVE PROBIOTIC BACTERIA BASED METHOD FOR DETERMINING TOXICITY TOWARDS PROBIOTIC BACTERIA

Information

  • Patent Application
  • 20160168616
  • Publication Number
    20160168616
  • Date Filed
    July 30, 2014
    10 years ago
  • Date Published
    June 16, 2016
    8 years ago
Abstract
A method for producing raw materials and finished products intended for food and pharmaceutical industries which are devoid of any toxicity toward probiotic bacteria is described. A probiotic bacteria-based toxicity test method is also described.
Description

The present invention relates to a method for producing raw materials and of finished products intended for the food and pharmaceutical industries and devoid of toxicity, which is detectable by means of an innovative method—based on probiotic bacteria—for analyzing toxicity toward probiotic bacteria.


All the materials or substances that are at the basis of the manufacture and production of other products through the use of appropriate processing and industrial processes that enable the desired final product to be obtained are considered raw materials.


The raw materials used in the production of food products or supplements or medical devices or pharmaceutical products include, by way of example, flavourings, extracts, co-formulants of organic and/or inorganic origin, technological additives, vitamins, proteins, amino acids, peptones, natural and/or synthetic polymers and still more.


By way of an illustrative and therefore non-exhaustive example, flavourings and/or extracts can be prepared from plants and/or their fruit.


It is well known that fruit-bearing plants and the fruit itself are today treated, for example, with chemical substances in order to protect them against the attacks of microorganisms or fungi or insects so as to enable the fruit to grow until reaching ripeness and then be harvested and consumed.


It is likewise well known that following said treatments, a part of the chemical substances used remains adsorbed on the exterior surface of the fruit, commonly called peel or rind. The chemical substances that are adsorbed also persist following successive washings of the fruit with water.


The peel (exocarp) is the protective outer layer of a fruit (epidermis, in turn made up of cuticle and sclerenchymatous tissue) or a vegetable which can be detached. The protective outer layer is also improperly called rind.


Furthermore, it cannot be ruled out that a part of the chemical substances adsorbed on the exterior surface of the fruit might penetrate into the fruit itself (into the flesh) as a result of absorption of said chemical substances from the outside toward the inside of the fruit.


Part of the fruit harvested is today used to produce natural vegetable extracts and/or flavourings (raw materials) that have application in the food, pharmaceutical and nutraceutical industries.


Usually, the natural vegetable extracts and/or flavourings are obtained by mechanical and/or chemical extraction from the whole fruit (peel and flesh) or from the peel and/or flesh treated separately, by means of the equipment and/or the techniques known to the person skilled in the art,


For example, in the case of flavourings and/or extracts and/or organic compounds obtained by extraction with solvents, it may occur that even by carrying out several washing steps with water and/or chemical solvents one does not succeed in completely eliminating all the solvent used; hence even a minimal presence can provoke toxicity to probiotic bacteria,


Therefore, it would be desirable to be able to have a method having high sensitivity and capable of identifying up until when there is a residual toxicity in a given substance or raw material in order to program the purification or washing or precipitation processes to be used to render the raw material free of toxicity to probiotic bacteria.


The same applies with reference to a protein extract or with reference to the preparation of amino acids. In this case as well, use is made of chemical reagents and/or solvents that can be left as residue and provoke toxicity to probiotic bacteria.


The same problem can also present itself with reference to inorganic raw materials, such as, for example silicon dioxide, widely used to formulate finished products.


With reference both to natural vegetable extracts and/or flavourings obtained by mechanical and/or chemical extraction and with reference to the other above-mentioned raw materials, prepared by means of processes of synthesis and/or extraction, one cannot disregard the fact that there may remain, within the raw material, minimal quantities of substances or compounds endowed with a “toxic” nature that impart a certain intrinsic toxicity to the raw material itself.


Therefore, with reference to natural vegetable extracts and/or with reference to the other above-mentioned raw materials, one cannot rule out the presence of toxic substances inside them in a variable quantity that can depend on the type of cultivation adopted for the fruit and/or the operating conditions adopted to carry out the mechanical and/or chemical extraction.


In any case, any toxic substances present in the natural vegetable extracts and/or flavourings and/or raw materials in general can give rise to two types of problems: an indirect one and a direct one.


The former, or indirect problem, is related to the influence that the intake of said toxic substances can have in altering the intestinal probiotic microflora and, therefore, also on the physiology of the digestive system, to such a point as to influence the absorption of vitamins, bioactive peptides and metabolites, and likewise permit the production of harmful biogenic amines, which are known to alter intestinal permeability and create a whole series of health problems, even arriving at the production of nitrosamine, well-known carcinogenic substances, said biogenic amines being produce by strains that have benefited from this alteration.


In this regard, it should be highlighted that, if the probiotic bacterial flora is altered as a result of an increase in the colonization of coliform pathogenic bacteria, such as, for example E. coli, endowed with decarboxylating properties capable of transforming an amino acid into an amine by eliminating the carboxyl group, abnormal quantities of harmful biogenic amines come to be produced.


Furthermore, an imbalance in intestinal microflora seems to be capable of contributing to the occurrence of various pathologies: diabetes and autoimmune diseases or, as has been hypothesized, to have a role in unbalanced local and systemic immune responses to certain food allergens.


The second, or direct problem, involves the effects that said toxic substances, already capable of killing the cells of probiotic bacteria, could have in individuals of paediatric age or in the development stage because of an immediate and/or accumulated toxic action, not only against bacterial cells but also against eukaryote cells, particularly sensitive in the differentiation and growth stage.


Thus there remains a need to be able to produce raw materials and finished products in an assuredly nontoxic manner and to have a method for determining the toxicity of an extract and/or a flavouring and/or a raw material in general that is sure, simple and practical to use, economical and repeatable.


In particular, there remains a need to have a method for determining the toxicity toward probiotic bacteria of the individual ingredients making up a finished product such as a food, a supplement, or a medical device or a drug.


The Applicant has found an innovative way of producing nontoxic raw materials and finished products, by subjecting the extracts and/or flavourings and/or raw materials in general to a new toxicity test in order to determine their toxicity toward probiotic bacteria.


The subject matter of the present invention is a method for producing nontoxic raw materials and finished products thanks to the possibility, provided by the Applicant, of being able to determine toxicity toward the probiotic bacteria present in said raw materials and finished products by means of an innovative method that likewise forms the subject matter of the present invention.


The Applicant has found that the toxicity determined with the method of the present invention depends not only on the raw material used per se, but also, and above all, on the type of mechanical and/or chemical extraction used to produce said raw material. In fact, the chemical extraction of a raw material can involve the use of chemical solvents, and some washing or precipitation steps that can leave residual toxicity in the raw material itself.


The method comprises a step in which the probiotic bacterial strain (toxicity marker) is placed in contact with a raw material to be tested using a quantity of raw material equal to that normally used in the formulation.


In practical terms, a first sample is prepared which comprises the probiotic bacterial strain (toxicity marker), the optimal culture substrate for said probiotic bacterial strain and the raw material to be tested.


Then a second sample (internal reference) is prepared which comprises the same probiotic bacterial strain used in said first sample (toxicity marker) and only the optimal culture substrate (without the raw material to be tested).


The determination takes place by means of a bacterial plate count of said first sample and said second sample, as described below.


The ratio between the bacterial count (number of cells counted on the plate) of said first sample and the bacterial count (number of cells on the plate) of said second sample provides a number less than 1, which, if expressed as a percentage, provides a count of the bacteria which survived in contact with the raw material and, therefore, also expresses the % mortality induced by said raw material in the probiotic bacterial strains used as a marker.


A first embodiment relates to determining the toxicity of a raw material, such as, for example, a natural vegetable extract and/or flavouring and/or raw material in general.


In this case, the test of toxicity toward the probiotic bacteria entails setting up two tests in the laboratory, as described above.


In practical terms, a first sample is prepared which comprises the probiotic bacterial strain (toxicity marker), the optimal culture substrate for said probiotic bacterial strain and the raw material to be tested.


Then a second sample (internal reference) is prepared which comprises the same probiotic bacterial strain used in said first sample (toxicity marker) and only the optimal culture substrate (without the raw material to be tested).


The determination takes place by means of a bacterial plate count of said first sample and said second sample, as described below.


Preferably, said first and second test are performed in parallel under the same operating conditions.


The ratio between the bacterial count (number of cells counted on the plate) of said first sample and the bacterial count (number of cells on the plate) of said second sample provides a number less than 1, which, if expressed as a percentage, provides a count of the bacteria which survived in contact with the raw material and, therefore, also expresses the % mortality induced by said raw material in the probiotic bacterial strains used as a marker.


The difference between the bacterial count performed in said first test and the bacterial count performed in said second test provides a percentage of bacterial mortality which provides an indication of the toxicity toward probiotic bacteria associated with said raw material.


The Applicant, by way of non-exhaustive example, tested several flavourings and extracts present in the market, such as, for example, lemon and blueberry flavourings, which are also used in the preparation of finished products. The aim of these tests was to verify whether said foods or raw materials (lemon and blueberry flavourings) possessed an intrinsic toxicity toward probiotic bacteria.


For this reason, said raw materials (lemon and blueberry flavourings) were placed in contact with given strains of probiotic lactic bacteria or bifidobacteria under particular operating conditions.


The probiotic bacterial strains used as a toxicity marker in the method of the present invention belong to the species selected from the groups comprising lactobacilli and bifidobacteria, preferably probiotic. Preferred embodiments envisage the use of a bacterial strain among those listed in Table 1.















TABLE 1







Commercial
Depositary
Deposit
Deposit



No.
Name
code
institution
number
date
Depositor





















1

Lactobacillus casei

LF1i
CNCM I.P.
I-785
21 Jul. 1988
Anidral Srl


2

Lactobacillus gasseri

LF2i
CNCM I.P.
I-786
21 Jul. 1988
Anidral Srl


3

Lactobacillus crispatus

LF3i
CNCM I.P.
I-787
21 Jul. 1988
Anidral Srl


4

Lactobacillus fermentum

LF4i
CNCM I.P.
I-788
21 Jul. 1988
Anidral Srl


5

Lactobacillus fermentum

LF5
CNCM I.P.
I-789
21 Jul. 1988
Anidral Srl


6

Lactobacillus casei ssp.

LFH i
CNCM I.P.
I-790
21 Jul. 1988
Anidral Srl




pseudoplantarum



7

Streptococcus thermophilus B39


BCCM LMG
LMG P-18383
5 May 1998
Anidral Srl


8

Streptococcus thermophilus T003


BCCM LMG
LMG P-18384
5 May 1998
Anidral Srl


9

Lactobacillus pentosus 9/1 ei


BCCM LMG
LMG P-21019
16 Oct. 2001
Mofin Srl


10

Lactobacillus plantarum 776/1 bi

LP 02
BCCM LMG
LMG P-21020
16 Oct. 2001
Mofin Srl


11

Lactobacillus plantarum 476LL 20 bi

LP 01
BCCM LMG
LMG P-21021
16 Oct. 2001
Mofin Srl


12

Lactobacillus plantarum PR ci


BCCM LMG
LMG P-21022
16 Oct. 2001
Mofin Srl


13

Lactobacillus plantarum 776/2 hi


BCCM LMG
LMG P-21023
16 Oct. 2001
Mofin Srl


14

Lactobacillus casei ssp. paracasei

LPC00
BCCM LMG
LMG P-21380
31 Jan. 2002
Anidral Srl



181A/3 aiai


15

Lactobacillus belonging to the

LA 02
BCCM LMG
LMG P-21381
31 Jan. 2002
Anidral Srl




acidophilus group 192A/1 aiai



16

Bifidobacterium longum 175A/1 aiai


BCCM LMG
LMG P-21382
31 Jan. 2002
Anidral Srl


17

Bifidobacterium breve 195A/1 aici


BCCM LMG
LMG P-21383
31 Jan. 2002
Anidral Srl


18

Bifidobacterium lactis 32A/3 aiai

BS 01
BCCM LMG
LMG P-21384
31 Jan. 2002
Anidral Srl


19

Lactobacillus plantarum 501/2 gi

COAKTIV
BCCM LMG
LMG P-21385
31 Jan. 2002
Mofin Srl


20

Lactococcus lactis ssp. lactis 501/4 ci


BCCM LMG
LMG P-21388
31 Jan. 2002
Mofin Srl


21

Lactococcus lactis ssp. lactis 501/4 hi


BCCM LMG
LMG P-21387
15 Mar. 2002
Mofin Srl


22

Lactococcus lactis ssp. lactis 501/4 ci


BCCM LMG
LMG P-21388
31 Jan. 2002
Mofin Srl


23

Lactobacillus plantarum 501/4 li


BCCM LMG
LMG P-21389
15 Mar. 2002
Mofin Srl


24

Lactobacillus acidophilus

LA08
BCCM LMG
LMG P-26144
3 Nov. 2010
Probiotical SpA


25

Lactobacillus paracasei ssp.

LPC10
BCCM LMG
LMG P-26143
3 Nov. 2010
Probiotical SpA




paracasei



26

Streptococcus thermophilus

GB1
DSMZ
DSM 16506
18 Jun. 2004
Anidral Srl


27

Streptococcus thermophilus

GB5
DSMZ
DSM 16507
18 Jun. 2004
Anidral Srl


28

Streptococcus thermophilus

Y02
DSMZ
DSM 16590
20 Jul. 2004
Anidral Srl


29

Streptococcus thermophilus

Y03
DSMZ
DSM 16591
20 Jul. 2004
Anidral Srl


30

Streptococcus thermophilus

Y04
DSMZ
DSM 16592
20 Jul. 2004
Anidral Srl


31

Streptococcus thermophilus

YO5
DSMZ
DSM 16593
20 Jul. 2004
Anidral Srl


32 =

Bifidobacterium adolescentis

BA 03
DSMZ
DSM 16594
21 Jul. 2004
Anidral Srl


56


33

Bifidobacterium adolescentis

BA 04
DSMZ
DSM 16595
21 Jul. 2004
Anidral Srl


34

Bifidobacterium breve

BR 04
DSMZ
DSM 16596
21 Jul. 2004
Anidral Srl


35

Bifidobacterium pseudocatenulatum

BP 01
DSMZ
DSM 16597
21 Jul. 2004
Anidral Srl


36

Bifidobacterium pseudocatenulatum

BP 02
DSMZ
DSM 16598
21 Jul. 2004
Anidral Srl


37

Bifidobacterium longum

BL 03
DSMZ
DSM 16603
20 Jul. 2004
Anidral Srl


38

Bifidobacterium breve

BR 03
DSMZ
DSM 16604
20 Jul. 2004
Anidral Srl


39

Lactobacillus casei ssp. rhamnosus

LR 04
DSMZ
DSM 16605
20 Jul. 2004
Anidral Srl


40

Lactobacillus delbrueckii ssp.

LDB 01
DSMZ
DSM 16606
20 Jul. 2004
Anidral Srl




bulgaricus



41

Lactobacillus delbrueckii ssp.

LDB 02
DSMZ
DSM 16607
20 Jul. 2004
Anidral Srl




bulgaricus



42

Staphylococcus xylosus

SX 01
DSMZ
DSM 17102
1 Feb. 2005
Anidral Srl


43 =

Bifidobacterium adolescentis

BA 02
DSMZ
DSM 17103
1 Feb. 2005
Anidral Srl


57


44

Lactobacillus plantarum

LP 07
DSMZ
DSM 17104
1 Feb. 2005
Anidral Srl


45

Streptococcus thermophilus

YO8
DSMZ
DSM 17843
21 Dec. 2005
Anidral Srl


46

Streptococcus thermophilus

YO9
DSMZ
DSM 17844
21 Dec. 2005
Anidral Srl


47

Streptococcus thermophilus

YO100
DSMZ
DSM 17845
21 Dec. 2005
Anidral Srl


48

Lactobacillus fermentum

LF06
DSMZ
DSM 18295
24 May 2006
Anidral Srl


49

Lactobacillus fermentum

LF07
DSMZ
DSM 18296
24 May 2006
Anidral Srl


50

Lactobacillus fermentum

LF08
DSMZ
DSM 18297
24 May 2006
Anidral Srl


51

Lactobacillus fermentum

LF09
DSMZ
DSM 18298
24 May 2006
Anidral Srl


52

Lactobacillus gasseri

LGS01
DSMZ
DSM 18299
24 May 2006
Anidral Srl


53

Lactobacillus gasseri

LGS02
DSMZ
DSM 18300
24 May 2006
Anidral Srl


54

Lactobacillus gasseri

LGS03
DSMZ
DSM 18301
24 May 2006
Anidral Srl


55

Lactobacillus gasseri

LGS04
DSMZ
DSM 18302
24 May 2006
Anidral Srl


56 =

Bifidobacterium adolescentis EI-3

BA 03
DSMZ
DSM 18350
15 Jun. 2006
Anidral Srl


32

Bifidobacterium catenulatum




sp./pseudocatenulatum EI-3I,



ID 09-255


57 =

Bifidobacterium adolescentis EI-15

BA 02
DSMZ
DSM 18351
15 Jun. 2006
Anidral Srl


43


58

Bifidobacterium adolescentis EI-18

BA 05
DSMZ
DSM 18352
15 Jun. 2006
Anidral Srl




Bifidobacterium animalis subsp.





lactis EI-18, ID 09-256



59

Bifidobacterium catenulatum EI-20

BC 01
DSMZ
DSM 18353
15 Jun. 2006
Anidral Srl


60

Streptococcus thermophilus FRai

MO1
DSMZ
DSM 18613
13 Sep. 2006
Mofin Srl


61

Streptococcus thermophilus LB2bi

MO2
DSMZ
DSM 18614
13 Sep. 2006
Mofin Srl


62

Streptococcus thermophilus LRci

MO3
DSMZ
DSM 18615
13 Sep. 2006
Mofin Srl


63

Streptococcus thermophilus FP4

MO4
DSMZ
DSM 18616
13 Sep. 2006
Mofin Srl


64

Streptococcus thermophilus ZZ5F8

MO5
DSMZ
DSM 18617
13 Sep. 2006
Mofin Srl


65

Streptococcus thermophilus TEO4

MO6
DSMZ
DSM 18618
13 Sep. 2006
Mofin Srl


66

Streptococcus thermophilus S1ci

MO7
DSMZ
DSM 18619
13 Sep. 2006
Mofin Srl


67

Streptococcus thermophilus 641bi

MO8
DSMZ
DSM 18620
13 Sep. 2006
Mofin Srl


68

Streptococcus thermophilus 277A/1ai

MO9
DSMZ
DSM 18621
13 Sep. 2006
Mofin Srl


69

Streptococcus thermophilus 277A/2ai

MO10
DSMZ
DSM 18622
13 Sep. 2006
Mofin Srl


70

Streptococcus thermophilus IDC11

MO11
DSMZ
DSM 18623
13 Sep. 2006
Mofin Srl


71

Streptococcus thermophilus ML3di

MO14
DSMZ
DSM 18624
13 Sep. 2006
Mofin Srl


72

Streptococcus thermophilus TEO3

MO15
DSMZ
DSM 18625
13 Sep. 2006
Mofin Srl


73

Streptococcus thermophilus G62

GG1
DSMZ
DSM 19057
21 Feb. 2007
Mofin Srl


74

Streptococcus thermophilus G1192

GG2
DSMZ
DSM 19058
21 Feb. 2007
Mofin Srl


75

Streptococcus thermophilus GB18

GG3
DSMZ
DSM 19059
21 Feb. 2007
Mofin Srl




MO2


76

Streptococcus thermophilus CCR21

GG4
DSMZ
DSM 19060
21 Feb. 2007
Mofin Srl


77

Streptococcus thermophilus G92

GG5
DSMZ
DSM 19061
21 Feb. 2007
Mofin Srl


78

Streptococcus thermophilus G69

GG6
DSMZ
DSM 19062
21 Feb. 2007
Mofin Srl


79

Streptococcus thermophilus

YO 10
DSMZ
DSM 19063
21 Feb. 2007
Anidral Srl


80

Streptococcus thermophilus

YO 11
DSMZ
DSM 19064
21 Feb. 2007
Anidral Srl


81

Streptococcus thermophilus

YO 12
DSMZ
DSM 19065
21 Feb. 2007
Anidral Srl


82

Streptococcus thermophilus

YO 13
DSMZ
DSM 19066
21 Feb. 2007
Anidral Srl


83

Weissella ssp. WSP 01

EX
DSMZ
DSM 19067
21 Feb. 2007
Anidral Srl


84

Weissella ssp. WSP 02

EX
DSMZ
DSM 19068
21 Feb. 2007
Anidral Srl


85

Lactobacillus ssp. WSP 03

EX
DSMZ
DSM 19069
21 Feb. 2007
Anidral Srl


86

Lactobacillus plantarum LP 09

OY
DSMZ
DSM 19070
21 Feb. 2007
Anidral Srl


87

Lactobacillus plantarum LP 10

OY
DSMZ
DSM 19071
21 Feb. 2007
Anidral Srl


88

Lactococcus lactis

NS 01
DSMZ
DSM 19072
21 Feb. 2007
Anidral Srl


89

Lactobacillus fermentum

LF 10
DSMZ
DSM 19187
20 Mar. 2007
Anidral Srl


90

Lactobacillus fermentum

LF 11
DSMZ
DSM 19188
20 Mar. 2007
Anidral Srl


91

Lactobacillus casei ssp.

LR05
DSMZ
DSM 19739
27 Sep. 2007
Anidral Srl




rhamnosus



92

Bifidobacterium bifidum

BB01
DSMZ
DSM 19818
30 Oct. 2007
Anidral Srl


93

Lactobacillus delbrueckii subsp.

Lb
DSMZ
DSM 19948
28 Nov. 2007
Anidral Srl




bulgaricus LD 01



94

Lactobacillus delbrueckii subsp.

Lb
DSMZ
DSM 19949
28 Nov. 2007
Anidral Srl




bulgaricus LD 02



95

Lactobacillus delbrueckii subsp.

Lb
DSMZ
DSM 19950
28 Nov. 2007
Anidral Srl




bulgaricus LD 03



96

Lactobacillus delbrueckii subsp.

Lb
DSMZ
DSM 19951
28 Nov. 2007
Anidral Srl




bulgaricus LD 04



97

Lactobacillus delbrueckii subsp.

Lb
DSMZ
DSM 19952
28 Nov. 2007
Anidral Srl




bulgaricus LD 05



98

Bifidobacterium pseudocatenulatum

B660
DSMZ
DSM 21444
13 May 2008
Probiotical SpA


99

Lactobacillus acidophilus

LA02
DSMZ
DSM 21717
6 Aug. 2008
Probiotical SpA


100

Lactobacillus paracasei

LPC 08
DSMZ
DSM 21718
6 Aug. 2008
Probiotical SpA


101

Lactobacillus pentosus

LPS 01
DSMZ
DSM 21980
14 Nov. 2008
Probiotical SpA


102

Lactobacillus rahmnosus

LR 06
DSMZ
DSM 21981
14 Nov. 2008
Probiotical SpA


103

Lactobacillus delbrueckii ssp.

DSMZ
DSMZ
DSM 22106
10 Dec. 2008
Probiotical SpA




delbrueckii

20074


104

Lactobacillus plantarum

LP1
DSMZ
DSM 22107
10 Dec. 2008
Probiotical SpA


105

Lactobacillus salivarius

LS01
DSMZ
DSM 22775
23 Jul. 2009
Probiotical SpA


106

Lactobacillus salivarius

LS03
DSMZ
DSM 22776
23 Jul. 2009
Probiotical SpA


107

Bifidobacterium bifidum

BB01
DSMZ
DSM 22892
28 Aug. 2009
Probiotical SpA


108

Bifidobacterium bifidum


DSMZ
DSM 22893
28 Aug. 2009
Probiotical SpA


109

Bifidobacterium bifidum

BB03
DSMZ
DSM 22894
28 Aug. 2009
Probiotical SpA


110

Bifidobacterium lactis

BS05
DSMZ
DSM 23032
13 Oct. 2009
Probiotical SpA


111

Lactobacillus acidophilus

LA 06
DSMZ
DSM 23033
13 Oct. 2009
Probiotical SpA


112

Lactobacillus brevis

LBR01
DSMZ
DSM 23034
13 Oct. 2009
Probiotical SpA


113

Bifidobacterium animalis ssp. lactis

BS06
DSMZ
DSM 23224
12 Jan. 2010
Probiotical SpA


114

Bifidobacterium longum

BL04
DSMZ
DSM 23233
12 Jan. 2010
Probiotical SpA


115

Bifidobacterium longum

BL05
DSMZ
DSM 23234
12 Jan. 2010
Probiotical SpA


116

Bifidobacterium bifidum

MB 109
DSMZ
DSM 23731
29 Jun. 2010
Probiotical SpA


117

Bifidobacterium breve

MB 113
DSMZ
DSM 23732
29 Jun. 2010
Probiotical SpA


118

Bifidobacterium lactis

MB 2409
DSMZ
DSM 23733
29 Jun. 2010
Probiotical SpA


119

Lactobacillus reuteri

LRE01
DSMZ
DSM 23877
5 Aug. 2010
Probiotical SpA


120

Lactobacillus reuteri

LRE02
DSMZ
DSM 23878
5 Aug. 2010
Probiotical SpA


121

Lactobacillus reuteri

LRE03
DSMZ
DSM 23879
5 Aug. 2010
Probiotical SpA


122

Lactobacillus reuteri

LRE04
DSMZ
DSM 23880
5 Aug. 2010
Probiotical SpA


123

Lactobacillus paracasei ssp.

LPC09
DSMZ
DSM 24243
23 Nov. 2010
Probiotical SpA




paracasei



124

Lactobacillus acidophilus

LA 07
DSMZ
DSM 24303
23 Nov. 2010
Probiotical SpA


125

Bifidobacterium bifidum

BB04
DSMZ
DSM 24437
4 Jan. 2011
Probiotical SpA


126

Lactobacillus crispatus

CRL 1251
DSMZ
DSM 24438
4 Jan. 2011
Probiotical SpA


127

Lactobacillus crispatus

CRL 1266
DSMZ
DSM 24439
4 Jan. 2011
Probiotical SpA


128

Lactobacillus paracasei

CRL 1289
DSMZ
DSM 24440
4 Jan. 2011
Probiotical SpA


129

Lactobacillus salivarius

CRL 1328
DSMZ
DSM 24441
4 Jan. 2011
Probiotical SpA


130

Lactobacillus gasseri

CRL 1259
DSMZ
DSM 24512
25 Jan. 2011
Probiotical SpA


131

Lactobacillus acidophilus

CRL 1294
DSMZ
DSM 24513
25 Jan. 2011
Probiotical SpA


132

Lactobacillus salivarius

LS04
DSMZ
DSM 24618
2 Mar. 2011
Probiotical SpA


133

Lactobacillus crispatus

LCR01
DSMZ
DSM 24619
2 Mar. 2011
Probiotical SpA


134

Lactobacillus crispatus

LCR02
DSMZ
DSM 24620
2 Mar. 2011
Probiotical SpA


135

Lacotbacillus acidophilus

LA09
DSMZ
DSM 24621
2 Mar. 2011
Probiotical SpA


136

Lactobacillus gasseri

LGS05
DSMZ
DSM 24622
2 Mar. 2011
Probiotical SpA


137

Lactobacillus paracasei

LPC11
DSMZ
DSM 24623
2 Mar. 2011
Probiotical SpA


138

Bifidobacterium infantis

BI 02
DSMZ
DSM 24687
29 Mar. 2011
Probiotical SpA


139

Bifidobacterium bifidum

BB 06
DSMZ
DSM 24688
29 Mar. 2011
Probiotical SpA


140

Bifidobacterium longum

BL 06
DSMZ
DSM 24689
29 Mar. 2011
Probiotical SpA


141

Bifidobacterium lactis

BS 07
DSMZ
DSM 24690
29 Mar. 2011
Probiotical SpA


142

Bifidobacterium longum

PCB133
DSMZ
DSM 24691
29 Mar. 2011
Probiotical SpA


143

Bifidobacterium breve

B632
DSMZ
DSM 24706
7 Apr. 2011
Probiotical SpA


144

Bifidobacterium breve

B2274
DSMZ
DSM 24707
7 Apr. 2011
Probiotical SpA


145

Bifidobacterium breve

B7840
DSMZ
DSM 24708
7 Apr. 2011
Probiotical SpA


146

Bifidobacterium longum

B1975
DSMZ
DSM 24709
7 Apr. 2011
Probiotical SpA


147

Lactobacillus salivarius

DLV1
DSMZ
DSM 25138
2 Sep. 2011
Probiotical SpA


148

Lactobacillus reuteri

LRE05
DSMZ
DSM 25139
2 Sep. 2011
Probiotical SpA


149

Lactobacillus reuteri

LRE06
DSMZ
DSM 25140
2 Sep. 2011
Probiotical SpA


150

Lactobacillus reuteri

RC 14
DSMZ
DSM 25141
2 Sep. 2011
Probiotical SpA


151

Streptococcus thermophilus

ST 10
DSMZ
DSM 25246
19 Sep. 2011
Probiotical SpA


152

Streptococcus thermophilus

ST 11
DSMZ
DSM 25247
19 Sep. 2011
Probiotical SpA


153

Streptococcus thermophilus

ST 12
DSMZ
DSM 25282
20 Oct. 2011
Probiotical SpA


154

Lactobacillus salivarius

DLV8
DSMZ
DSM 25545
12 Jan. 2012
Probiotical SpA


155

Bifidobacterium longum

DLBL 07
DSMZ
DSM 25669
16 Feb. 2012
Probiotical SpA


156

Bifidobacterium longum

DLBL 08
DSMZ
DSM 25670
16 Feb. 2012
Probiotical SpA


157

Bifidobacterium longum

DLBL 09
DSMZ
DSM 25671
16 Feb. 2012
Probiotical SpA


158

Bifidobacterium longum

DLBL 10
DSMZ
DSM 25672
16 Feb. 2012
Probiotical SpA


159

Bifidobacterium longum

DLBL 11
DSMZ
DSM 25673
16 Feb. 2012
Probiotical SpA


160

Bifidobacterium longum

DLBL 12
DSMZ
DSM 25674
16 Feb. 2012
Probiotical SpA


161

Bifidobacterium longum

DLBL13
DSMZ
DSM 25675
16 Feb. 2012
Probiotical SpA


162

Bifidobacterium longum

DLBL 14
DSMZ
DSM 25676
16 Feb. 2012
Probiotical SpA


163

Bifidobacterium longum

DLBL 15
DSMZ
DSM 25677
16 Feb. 2012
Probiotical SpA


164

Bifidobacterium longum

DLBL 16
DSMZ
DSM 25678
16 Feb. 2012
Probiotical SpA


165

Bifidobacterium longum

DLBL 17
DSMZ
DSM 25679
16 Feb. 2012
Probiotical SpA


166

Lactobacillus johnsonii

DLLJO 01
DSMZ
DSM 25680
16 Feb. 2012
Probiotical SpA


167

Lactobacillus rhamnosus

DLLR 07
DSMZ
DSM 25681
16 Feb. 2012
Probiotical SpA


168

Lactobacillus rhamnosus

DLLR 08
DSMZ
DSM 25682
16 Feb. 2012
Probiotical SpA


169

Lactobacillus reuteri

DLLRE 07
DSMZ
DSM 25683
16 Feb. 2012
Probiotical SpA


170

Lactobacillus reuteri

DLLRE 08
DSMZ
DSM 25684
16 Feb. 2012
Probiotical SpA


171

Lactobacillus reuteri

DLLRE 09
DSMZ
DSM 25685
16 Feb. 2012
Probiotical SpA


172

Bifidobacterium longum

DLBL 18
DSMZ
DSM 25708
24 Feb. 2012
Probiotical SpA


173

Bifidobacterium infantis

BI 03
DSMZ
DSM 25709
24 Feb. 2012
Probiotical SpA


174

Lactobacillus plantarum

LP 09
DSMZ
DSM 25710
24 Feb. 2012
Probiotical SpA


175

Bifidobacterium longum

DLBL 19
DSMZ
DSM 25717
1 Mar. 2012
Probiotical SpA


176

Bifidobacterium longum

DLBL 20
DSMZ
DSM 25718
1 Mar. 2012
Probiotical SpA


177

Lactobacillus salivarius

LS 05
DSMZ
DSM 26036
6 Jun. 2012
Probiotical SpA


178

Lactobacillus salivarius

LS 06
DSMZ
DSM 26037
6 Jun. 2012
Probiotical SpA


179

Lactobacillus pentosus

LPS 02
DSMZ
DSM 26038
6 Jun. 2012
Probiotical SpA


180

Bifidobacterium pseudolongum

BPS 01
DSMZ
DSM 26456
2 Oct. 2012
Probiotical SpA



ssp. globosum


181

Lactobacillus fermentum

LF15
DSMZ
DSM 26955
1 Mar. 2013
Probiotical SpA


182

Lactobacillus fermentum

LF16
DSMZ
DSM 26956
1 Mar. 2013
Probiotical SpA


183

Lactobacillus casei

LC03
DSMZ
DSM 27537
24 Jul. 2013
Probiotical SpA


184

Lactobacillus crispatus

LCR03
DSMZ
DSM 27538
24 Jul. 2013
Probiotical SpA


185

Lactobacillus jensenii

LJE01
DSMZ
DSM 27539
24 Jul. 2013
Probiotical SpA









The tests performed on said foods or raw materials (lemon and blueberry flavourings) showed an acute toxicity toward the probiotic bacterial strains used as toxicity markers. In practical terms, two lemon extracts (raw material) and two blueberry extracts of (raw material) from different suppliers were tested. It was possible to verify that a first lemon extract and a second blueberry one provoked an acute toxicity, 57% and 58% mortality respectively, toward the probiotic bacterial strains used having an initial theoretical load of 6×109 CFU/g. The tests were performed using the probiotic bacterial strain Lactobacillus acidophilus LA02 LMG P-21381 deposited by the company Anidral Srl on Jan. 13, 2002, and the probiotic bacterial strain Bifidobacterium animalis subsp. Lactis BS01 LMG P-21384 deposited by the company Anidral Srl on Jan. 13, 2002.


At this point the Applicant replicated the aforesaid tests using, in place of the blueberry and lemon flavourings present in the market, flavourings obtained only from the flesh of the fruit (lemon and blueberry) by gentle squeezing. In practical terms, in the case of both lemon and blueberry, the peel was separated from the flesh beforehand and only the latter was subjected to mechanical extraction under gentle conditions, using equipment and methods known to the person skilled in the art. In this case, with the extracts/raw materials obtained from an extraction of the flesh under gentle conditions, toxicity toward the probiotic bacteria was found to be inexistent; in fact, using an initial load of the probiotic bacterial strain equal to 6.7×109 CFU/g, 6.5×109 CFU/g were obtained with blueberry juice and 6.4×109 CFU/g with lemon juice, hence much better values than in the previous case with very low toxicity and a mortality close to zero.


Other raw materials were tested in the same way as the lemon and blueberry extracts, as described below.


The Applicant tested several finished products present in the market with the aim of determining the degree of toxicity toward probiotic bacteria and identify, among the raw materials used in said finished products, which of the raw materials used contributed most to the toxicity.


In a preferred embodiment, the toxicity of a raw material toward probiotic bacteria is determined, the raw material being for example an extract and/or a flavouring that is within a formulation of a finished product having, for example, a total of 5 components.


In this case, the toxicity test involves setting up a number of tests in the laboratory equal to the number of components—in this exemplifying case there are 5 components, plus the analytical references.


In order to show the potentiality of the present invention, the Applicant tested a series of samples of cranberry extract to be used in the preparation of a finished product, for example P1.


The toxicity of the raw material, cranberry extract (lot L1, lot L2, from four different suppliers) which must be present together with other components/ingredients within a finished product (P1) was determined.


In this case, two tests were set up. In a first test, a mixture consisting of a probiotic bacterial strain, for example LS01 (used as the toxicity marker) was prepared. This first test represents the internal analytical reference—Ref. 1. The expected theoretical bacterial count was equal to 25 MLD/dose (internal reference).


In a second test, a mixture containing the probiotic bacterial strain LS01 (used as the toxicity marker) together with a first cranberry extract—L1 and L2, in said finished product, from different suppliers, was prepared.


Said first and second bacterial counts were performed in parallel under the same operating conditions and with the same amounts as those present in said finished product.


Subsequently, the real bacterial count of said first test—Ref. 1 and the bacterial count of said second test were determined. The bacterial count was carried out adopting the same operating conditions.


Supplier V: lot 1 (L1) and lot 2 (L2)—Var cranberry


Supplier V: lot 1 (L1) and lot 2 (L2)—Var cranberry


Supplier K: lot 1 (L1) and lot 2 (L2)—Kem cranberry


Supplier K: lot 1 (L1) and lot 2 (L2)—Kem cranberry


Supplier P: lot 1 (L1) and lot 2 (L2)—Pac cranberry


Supplier P: lot 1 (L1) and lot 2 (L2)—Pac cranberry


Supplier N: lot 1 (L1) and lot 2 (L2)—Nut cranberry


Supplier N: lot 1 (L1) and lot 2 (L2)—Nut cranberry


The various supplies (lots) of the raw material, cranberry, were introduced into the mixture for the toxicity test based on their proanthocyanidin content (at least 1.5% (HPLC)), so at to ensure the same concentration of that ingredient in the finished product P1.












TABLE 2







Load MLD/
% mortality


Mixture to be tested
Lot
dose
vs Ref. 1


















Bacterial strain LS01 (real load -Ref.

25



1)


Mixture: bacterial strain LS01 + Var
L1
1.2
95


cranberry extract [Supplier V]


Mixture: bacterial strain LS01 + Var
L2
0.9
96


cranberry extract [Supplier V]


Mixture: bacterial strain LS01 + Kem
L1
0.8
97


cranberry extract [Supplier K]


Mixture: bacterial strain LS01 + Kem
L2
2
91


cranberry extract [Supplier K]


Bacterial strain LS01 (real load -Ref.

22


1)


Mixture: bacterial strain LS01 + Pac
L1
20
9


cranberry extract [Supplier P]


Mixture: bacterial strain LS01 + Pac
L2
20
9


cranberry extract [Supplier P]


Bacterial strain LS01 (real load -Ref.

20


1)


Mixture: bacterial strain LS01 + Nut
L1
14
30


cranberry extract [Supplier N]


Mixture: bacterial strain LS01 + Nut
L2
9
55


cranberry extract [Supplier N]









The tests of Table 2 were also repeated with the probiotic bacterial strains indicated in Table 1 with the numbers 9, 33, 39, 46, 54, 59, 73, 84, 95, 101, 116, 130, 138, 143, 169 and 185 and the results obtained were very similar to those shown in Table 2.


The difference between the bacterial count performed in said first test—Ref.1 and the bacterial count performed in said second test provides a percentage of mortality of the probiotic bacterial strain LS01, which provides an indication of the toxicity of said cranberry extract towards said strain.


The viable cell load obtained from the bacterial count, as determined in said first test and in said second test, makes it possible to establish whether the tested raw material exerts a toxic effect on the cells of the probiotic bacterial strain LS01 present in said finished product P1.


The percentage decrease in the bacterial count compared to the reference—Ref.1 is expressed as % mortality induced by the raw material subjected to the toxicity test of the present invention.


The Applicant further applied the above-described method to lemon and blueberry extracts present in a finished product, obtaining results comparable to the ones obtained above with cranberry.


Table 2 shows that there are extracts, for example cranberry extract, which is commonly used to formulate finished products—but the same consideration also applies with reference to other raw materials—which impart toxicity to finished products and, consequently, also to the body of individuals who use said finished products.


Therefore, with the present invention it is possible to develop formulations of finished products such as dietary supplements or medical devices or pharmaceutical products devoid of toxicity or with greatly reduced toxicity, since it is possible to identify whether the raw materials used impart toxicity toward probiotic bacteria.


In the context of the present invention a percentage decrease in the bacterial load compared to the internal reference [(Bacterial count of the test sample)/(Bacterial count of the internal reference)]=% mortality induced by the raw material comprised from 1 to 5% signifies no mortality; a value comprised from greater than 5 to 15% signifies a low mortality, still acceptable; a value comprised from greater than 15 to 25% signifies medium-high mortality, whereas beyond 25% we are facing acute mortality.


The method of the present invention has valid application, for example, in testing for the presence of toxic excipients or raw materials used in the formulations of supplements and medical devices (finished products), such as, for example, orange flavouring, safflower, black carrot, blueberry extract etc.).


The method of the present invention is illustrated below by way of example and therefore does not limit of the scope of the present invention.


In a preferred embodiment, in the case of a finished product containing, for example, the following components A, B, C (complete formulation A+B+C), the method of the present invention can be used in order to determine whether the finished product as a whole (A+B+C) exerts toxicity towards the probiotic bacterial strains.


In this case, the test of the toxicity toward the probiotic bacteria involves setting up two tests in the laboratory.


In practical terms, a first sample is prepared which comprises the probiotic bacterial strain (toxicity marker), the optimal culture substrate for said probiotic bacterial strain and the raw material to be tested, in this case the formulation A+B+C.


Then a second sample (internal reference) is prepared which comprises the same probiotic bacterial strain used in said first sample (toxicity marker) and only the optimal culture substrate (without the raw material to be tested).


The determination takes place by means of a bacterial plate count of said first sample and said second sample.


Preferably, said first and second tests are performed in parallel under the same operating conditions.


If the ratio between the bacterial count (number of cells counted on the plate) of said first sample and the bacterial count (number of cells counted on the plate) of said second sample provides a number lower than 1, for example 0.55 (or 55%), it means that the count of the bacteria that have survived in contact with the raw material is 55% and, therefore, the % mortality induced by A+B+C in the probiotic bacterial strain used as the marker is 45%.


If, precisely, a toxicity toward the probiotic bacterial strain used as a marker emerges, the next step is to go and determine which of the components A, B and C making up the finished product (A+B+C), exerts the detected toxicity.


In this case, the method involves preparing three tests (test 1, test 2 and test 3) as specified below.


For example, test 1 is performed on raw material A and involves preparing the following samples:


(i) A first sample is prepared which comprises the probiotic bacterial strain (toxicity marker), the optimal culture substrate for said probiotic bacterial strain and the raw material to be tested, in this case A.


(ii) A second sample (internal reference) is prepared which comprises the same probiotic bacterial strain used in said first sample (toxicity marker) and only the optimal culture substrate (without the raw material to be tested).


(iii) A bacterial plate count is performed on said first sample and said second sample.


(iv) The percentage of mortality is determined.


Analogously, test 2 with raw material B and test 3 with raw material C are prepared with the same method. In this manner, it is possible to identify which, among the components A, B and C present in the formulation A+B+C, is the component that exerts toxicity towards probiotic bacterial strains. The toxicity tests are performed under the same operating conditions and at the concentrations indicated in the finished product—sequential approach.


For the plate count one follows the method, described below by way of non-limiting example of a test method, which comprises a traditional microbiological count with initial resuspension of the sample, serial dilutions in a suitable diluent, plating on an agarized medium and a colony count after incubation under optimal conditions. The excipients/raw materials that determine a plate mortality comparable with that of the reference sample are to be considered as conforming (reduced toxicity or no toxicity whatsoever).


As noted above, one performs a total, differential and/or selective (in an agarized medium) count of lactic bacteria and bifidobacteria for probiotic use, present alone or in admixture in the sample to be subjected to a determination of the concentration of live, viable cells.


The formulation of the culture medium is such as to ensure the growth of all the various species of probiotic bacteria belonging to the aforesaid microbial groups and if necessary to enable them to be discriminated by adding selective agents (generally antibiotics and/or sugars) or differential ones (generally pH and/or redox colour change indicators).


The method provides for the use of the agarized medium LAPTg, whose formulation consists solely in the presence of two different nitrogen sources, a sugar as a source of carbon, and yeast extract as a source of group B vitamins and growth factors. The absence of organic and inorganic salts and substances with selective action allows a flourishing growth of all the various species of probiotic bacteria belonging to the genera Lactobacillus and Bifidobacterium.


By adding a selective and/or differential agent to the LAPTg agar it is possible to perform differentiated counts of the probiotics present in a complex mixture. The selective agents (generally antibiotics and/or sugars) or differential ones (generally pH and/or redox colour change indicators) are selected case by case on the basis of the specific genotypic and phenotypic characteristics of the strains making up the mixture.


If the sample to be analyzed consists of a mixture of two or more strains of lactobacilli and bifidobacteria, it is advisable to accompany the selective count in LAPTg with a qualitative assessment of the strains making up the mixture using HHD medium. For further details, reference is made to the following scientific articles:



Molecular Cloning a Laboratory Manual (Sambrook, Fritsch, Maniatis);



Susceptibility of Lactobacillus spp. to antimicrobial agents. M. Danielsen A. Wind. 2002;



Antibiotic Susceptibility of Lactobacillus and Bifidobacterium species from Human Gastrointestinal tract, S. Delgrado A. B. Florez B. Mayo, 2005;


ISO 6887-1:2000


Preparation of LAPTg medium: FONT DE VALDEZ, G, and coll.: Influence of the recovery medium on the viability of injured freeze-dried lactic acid bacteria Milchwissenschaft 40 (9) 518-520 (1985).


UNI EN ISO 6887-1:2000 “Buffered Peptone Water”



A differential medium for the enumeration of homofermentative and heterofermentative lactic acid bacteria. L C. McDonald R. F. McFeeters, M. A. Daeschel and H P Felminq. Applied and Environmental Microbiology. June 1987: 1382-1384.


Initials and Abbreviations:


concentration of live, viable cells=no. of cells/units (g or ml) able to grow in the culture medium and form distinct colonies (CFU/g or ml)


CFU/g or ml=Colony Forming Unit, i.e. unit of measure of the concentration of live, viable cells


MIC=Minimum Inhibitory Concentration


The method provides for the use of the agarized medium LAPTg, whose formulation consists solely in the presence of two different nitrogen sources, a sugar, as a source of carbon, and yeast extract as a source of group B vitamins and growth factors. The absence of organic and inorganic salts and substances with selective action allows a flourishing growth of all the various species of probiotic bacteria belonging to the genera Lactobacillus and Bifidobacterium. By adding a selective and/or differential agent to LAPTg agar it is possible to perform differentiated counts of the probiotics present in a complex mixture. The selective agents (generally antibiotics and/or sugars) or differential ones (generally pH and/or redox colour change indicators) are selected case by case on the basis of the specific genotypic and phenotypic characteristics of the strains making up the mixture. (see 8.2). If the sample to be analyzed consists of a mixture of two or more strains of lactobacilli and bifidobacteria, it is advisable to accompany the selective count in LAPTg with a qualitative assessment of the strains making up the mixture using HHD medium.


Materials and Reagents:


LAPTg Medium, Basal Medium:


Bacto Peptone (enzymatic hydrolysate of animal protein) 15 g


Tryptone (pancreatic hydrolysate of casein) 10 g


Yeast extract 10 g


Tween 80 ml 1


Agar g 15


Distilled water q.s. to 900 ml


Note: the weights indicated above are understood as having an accuracy of ±5%


Dissolve the components in the distilled water, except for the agar. Check the pH and correct if necessary to 6.55±0.05, then add the agar and dissolve in a water bath. Dispense the medium while still warm into the Bibby beakers, and sterilize in an autoclave at 121° C. for 15 minutes; after sterilization the pH should be 6.5±0.5 at 25° C.±1.


Complete Medium:


At the time of use, after dissolution (8.1), add one volume of a 10% glucose solution, sterilized by filtration, to the basal medium, so as to have a final glucose concentration of 10 g/litre.


HHD Medium:



















Fructose
2.50
g



KH2PO4
2.50
g



Bacto Tryptone
10.00
g



Soytone Peptone
1.50
g



Casamino acids
3.00
g



Yeast extract
10.00
g



Tween 80
1.00
g



Bromocresolgreen
20.00
ml



Agar
20.00
g



Distilled water
1000
ml







Final pH = 6.90 + 0.10.






Ethanol, Minisart single-use sterile 0.45 μm syringe filters, diluents for reconstituting the samples:


Reconstitution of liquid bacterial cultures and preparation of serial decimal dilutions—peptone saline solution



















bacto peptone
1.0
g



sodium chloride (NaCl)
8.5
g



distilled water q.s to
1000
ml










Reconstitution of anhydrous (lyophilized) bacterial cultures and finished products with probiotics in free form (not microencapsulated).












Lyophilized) bacterial cultures not prepared in doses or units


Phosphate buffer pH 6.8



















sodium chloride (NaCl)
5.00
g



KH2PO4
3.78
g



Na2HPO4
4.77
g



distilled water q.s. to
1000
ml










Sachets, capsules, pills, tablets, suppositories and undercaps of bottles:












Phosphate buffer pH 6.8


















sodium chloride (NaCl)
g 5.00



KH2PO4
g 3.78



Na2HPO4
g 4.77



distilled water q.s. to
ml 1000










Dissolve the components in distilled water, heating if necessary. Check that the pH is 6.8±0.10. Dispense the diluents into Bibby beakers, sterilize in an autoclave at 121° C. for 15 minutes, and store in darkness at a temperature of 4-5° C. for no longer than one month.


Should the finished products contain oils and/or lipid substances it will be necessary to add 1% Tween 80 to the buffer pH 6.8 (5.5.2,1).


Anaerobic kit (AnaeroGen—Oxoid): chemically binds oxygen, producing CO2; small 10 ml non-sterile syringes also purchasable in pharmacies; 5%fin L-cysteine HCI solution: weigh out 5 g of L-cysteine hydrochloride 1-hydrate (BDH 370553) and bring to 100 ml with MQ water; then filter in a sterile falcon tube with a 0.45 μm filter and store at +4° C.±2 for up to 1 year (the solution will have to be added to the LAPTg medium so as to obtain a final concentration of 0.05%).


Procedure.


8.1 Dissolve the LAPTg medium (5.1) in a sufficient amount for the number of plates to be prepared (see note in paragraph 8.5.5), considering that for each plate about 12±1 ml of medium is necessary.


If it is planned to perform a count on the same dilutions of the sample not only in the LAPTg medium as such, but also in the same supplemented with one or more selective agents (N), consider the (no. of plates) multiplied by N. Leave the medium a thermostated water bath at a temperature of 45° C.±0.5 for at least 3 hours;


8.2 List of selective agents and respective preparation












8.2.1 Antibiotics







VANCOMICIN








stock solution
1 mg/ml (sterilized by filtration 0.45 μm)


diluent
water


usage concentration
1 μg/ml


positive selection
obligate and facultative heterofermenter lactobacilli (e.g. L. plantarum, L. rhamosus,




L. casei, L. paracasei etc.).



negative selection
sensitive strains such as homofermenter lactobacilli (e.g. L. acidophilus



group) and bifidobacteria.







Storage: 1.5 ml aliquots at +4° C. for 15 days or at −20° C. for up to 4 months.







CHLORAMPHENICOL








stock solution
10 mg/ml (sterilized by filtration 0.45 μm)


diluent
ethanol


usage concentration
70 μg/ml


positive selection
strains with MIC >4 μg/ml (e.g. LPC 00)


negative selection
strains with higher sensitivity (MIC <2 μg/ml).







Storage: 2 ml aliquots at −20° C. for up to 4 months.







CLINDAMYCIN + CIPROFLOXACIN








stock solution
1 mg/ml clindamycin + 10 mg/ml ciprofloxacin (sterilized by filtration 0.45 μm)


diluent
water (in case of poor dissolution of the ciprofloxacin, add 1-2 drops of



concentrated lactic acid).


usage concentration
0.1 μg/ml clindamycin and 10 μg/ml ciprofloxacin


positive selection

L. acidophilus group



negative selection

L. rhamosus, L. casei, L. paracasei, L, plantarum, L. reuteri, L. delbrueckii,




bifidobacteria, lattococci and Streptococcus thermophilus.







Storage: 1.5 ml aliquots at −20° C. for up to 6 months for ciprofloxacin (clindamycin n.d.).







CEFUROXIME








stock solution
1 mg/ml (sterilized by filtration 0.45 μm)


diluent
water


usage concentration
0.1 μg/ml


positive selection
strains with MIC >1 (e.g. B. longum PCB 133)


negative selection

Streptococcus thermophilus (e.g. YO 8) and other strains with MIC ≦0.016.








Storage: 1.5 ml aliquots at −20° C. for up to 2 years.







CEFOXITIN








stock solution
10 mg/ml (sterilized by filtration 0.45 μm)


diluent
water


usage concentration
100 μg/ml


positive selection
strains with MIC >256 (e.g. LGG, LPC 08, LC 01)


negative selection
LP 01, LP 02, L. acidophilus group and other sensitive strains with MIC <24.







Storage: 1.5 ml aliquots at −20° C. for up to 2 years.







MUPIROCIN








stock solution
10 mg/ml (sterilized by filtration 0.45 μm)


diluent
water


usage concentration
50 μg/ml


positive selection
Bifidobacteria


negative selection
Lactobacilli.







Storage: 1.5 ml aliquots at −20° C. for up to 6 months







CIPROFLOXACIN (positive selection LP02 in admixture with LF10).








stock solution
10 mg/ml (sterilized by filtration 0.45 μm)


diluent
water (in case of poor dissolution of the ciprofloxacin, add 1-2 drops of



concentrated lactic acid)


usage concentration
5 μg/ml


positive selection
LP02


negative selection
LF10.







Storage: 1.5 ml aliquots at −20° C. for up to 6 months









8.2.2 Other selective conditions.


8.3 If the sample to be analyzed consists of a mixture of two or more strains of lactobacilli and/or bifidobacteria, it is advisable to accompany the selective count in LAPTg with a qualitative assessment of the strains making up the mixture using HHD medium. Dissolve the aforesaid medium and leave it in a thermostated bath as described for the LAPTg medium. Then distribute the medium in amounts of 12±1 ml in Petri plates and allow to solidify;


8.4 If it is planned to use one or more selective agents, add the antibiotic solution or other selective agent necessary for discriminating the strains making up the sample to an aliquot (e.g. 100 ml for about 8 plates) of the dissolved LAPTg medium, at the final concentration indicated, in a sterile bottle;


8.5 Prepare successive decimal dilutions of the sample (section Ia ISO 6887-1:2000 par. 9.2.)


8.5.1 Use a sterile pipette to transfer 1 ml of the primary dilution, or 1 ml directly from the sample culture if liquid, into a test tube containing 9 ml of sterile diluent;


8.5.2 do not introduce the pipette deeper than 1 cm into the initial suspension;


8.5.3 change the pipette after every dilution;


8.5.4 thoroughly homogenize the dilution with a mechanical shaker, vortexing the tube 3 times for a time of no less than 5 seconds, so as to obtain the dilution 10−2;


8.5.5 repeat these steps using the dilution 10−2 and dilute further until obtaining a concentration of microorganisms which, when cultured on a plate, give a significant number of colonies;


It should be noted that seeding 2 successive decimal dilutions (e.g.: 10−8, 10−9) should enable two contiguous dilutions containing a number of cells comprised from 10 to 300 to be found. If there is no clear idea as to the number of cells contained in the sample, it will be necessary to seed more than 2 successive decimal dilutions (e.g.: 10−5, 10−6, 10−7, 10−8, 10−9, 10−10) and then consider only the ones that give rise to a number of colonies comprised from 10 to 300.


8.6 distribute 1 ml, drawn from the dilutions of the sample judged to be appropriate (8.5.5), onto the Petri plates;


8.7 add the medium LAPTg on the first series of plates and LAPTg supplemented with the selective agent on the second series, in amounts of 12±1 ml;


It should be noted that the time elapsing between the reconstitution of the sample and the moment at which the serial dilution comes into contact with the culture medium on the Petri plate (8,6) must not exceed 30 minutes


8.8 evenly mix the medium and sample, first with rotational movements, and then horizontal and vertical translational ones;


8.9 allow to solidify for 15-20 minutes;


8.10 in the case of samples consisting of a mixture of two or more strains of lactobacilli and bifidobacteria and/or for which it is recommended to use the HHD medium, add 100 μl of the appropriate dilutions to the ready plates of HHD (8.3) and distribute the sample evenly with a spatula;


8.11 incubate the plates upside down at 37±1° C. for 72 h under anaerobic conditions (Gas-Pak+anaerobic kit). As to how to use the anaerobic system, follow the instructions included with the kit. Calculation of the results: verify the presence of colonies by observing them under the lens of the plate viewer and count exclusively the plates containing a number of colonies comprised from 10 to 300. The result will be expressed as CFU, i.e. Colony Forming Units. Express the result using the following formula:







Σ





C



(



n
1

+
0

,

1






n
2



)


d





where:


ΣC is the sum of the colonies counted on all the plates


n1 is the number of plates counted in the first dilution


n2 is the number of plates counted in the second dilution


d is the dilution the first counts were obtained from







EXAMPLE





    • Plates of dilution 10−8: 250

    • Plates of dilution 10−9: 23





Result:








250
+
23



(

1
+
0.1

)



10

-
8




=

248






10

-
8







CFU


/


g





Round off the result obtained to two significant digits. The results of the example shown will thus be 250 10−8 CFU/g or ml in the case of liquid samples (for the detail of the expression of results based on the specific type. In the case of samples spread in HHD, visually examine the different morphologies of the cultured colonies which identify the various strains of lactobacilli and bifidobacteria present in admixture.


After performing the count and examining the plate-cultured colonies (step 9) one has: in the case of single-strain samples, the count obtained from the plates with LAPTg as such represents the total load of the probiotic load making up the sample.


In the case of samples consisting of a mixture of two or more strains of lactobacilli and bifidobacteria:


a) the count obtained from the series of plates prepared with the LAPTg medium as such represents the total load of the probiotic bacteria in the sample subjected to analysis;


b) the count obtained from the series of plates prepared with the LAPTg medium supplemented with the selective agent represents the load of the strain(s) that were capable of replicating in the presence of that specific substance added to the medium as a selective agent.


c) from the count regarding the individual probiotic strains, obtained with the selective medium, it is possible to derive the count of the remaining strain(s) that did not develop in the presence of the selective agent by calculating the difference with the total count (letter a) in LAPTg as such.


d) seeding in HHD medium makes it possible to visually discriminate the different strains present in the sample in admixture and selectively enumerated in LAPTg medium.


The Applicant tested the following raw materials with the method of the present invention in a number of tests using the probiotic bacterial strains indicated in Table 1 with the numbers 17, 22, 41, 60, 74, 98, 121, 145, 174 and 182 as toxicity markers.


Experimental data show that in many cases toxicity was unexpectedly found always to be present at various levels, along with a substantial % mortality.


Aloe test: mortality found equal to 5%.


Citric Acid test: mortality found equal to 2%.


Arabinogalactan test: mortality found equal to 6%.


Raspberry flavouring test: mortality found equal to 2%.


Raspberry flavouring test: mortality found equal to 26%.


Blueberry test: mortality found equal to 5%.


Silicon dioxide test: mortality found equal to 50%.


Silicon dioxide test: mortality found equal to 28%.


Silicon dioxide test: mortality found equal to 23%.


Tara gum test: mortality found equal to 14%.


Vitamin B1, B2 and B6 test: mortality found equal to 33%.


Zeolite test: mortality found equal to 2%.

Claims
  • 1. A method for testing toxicity of a food or pharmaceutical raw material; the method comprising: placing a raw material in contact with a pre-established bacterial load of at least one probiotic bacterial strain; anddetecting a reduction of said pre-established bacterial load due to the toxicity exerted by said raw material toward said at least one probiotic bacterial strain.
  • 2. The method according to claim 1, wherein the placing comprises: preparing a first test sample comprising the at least one probiotic bacterial strain at a pre-established concentration, an optimal culture substrate for the growth of said probiotic bacterial strain and the food or pharmaceutical raw material to be tested, andpreparing a second test sample comprising the probiotic bacterial strain of said first sample at the pre-established concentration and the optimal culture substrate for the growth of said at least one probiotic bacterial strain.
  • 3. The method according to claim 2, wherein the detecting comprises performing a bacterial count on said first and said second test samples.
  • 4. The method according to claim 3, wherein the performing a bacterial count on said first and second test samples comprises: for each of said first and second test samples re-suspending the test sample,making serial dilutions in a suitable diluent,plating in an agarized medium andcounting on a plate the colonies after incubation under optimal conditions.
  • 5. The method according to claim 4, further comprising: detecting a ratio between a first bacterial count of said first test sample and a second bacterial count of said second test sample,wherein the first bacterial count is a first number of cells counted on a plate containing the first test sample and the second bacterial count is a second number of cells counted on a plate containing the second test sample.
  • 6. The method according to claim 1, wherein the at least one probiotic bacterial strain used as a marker of toxicity toward probiotic bacteria is selected from lactobacilli and bifidobacteria.
  • 7. The method according to claim 1, wherein said food or pharmaceutical raw material is selected from the group comprising flavourings, extracts, co-formulants of organic and/or inorganic origin, technological additives, vitamins, proteins, amino acids, peptones, natural and/or synthetic polymers and others.
  • 8. A method for producing food products or dietary supplements or medical devices or pharmaceutical products comprising raw materials that are not toxic toward a probiotic bacteria toxicity marker, comprising: subjecting the food products or dietary supplements or medical devices or pharmaceutical products to a toxicity test using the method for testing toxicity of a food or pharmaceutical raw material according to claim 1.
  • 9. The method according to claim 1, wherein the at least one probiotic bacterial strain is a toxicity marker.
  • 10. The method according to claim 2, wherein the second test sample is an internal reference.
  • 11. The method according to claim 2, wherein the pre-established concentration of the at least one probiotic bacterial strain is from 1×106 to 1×109 CFU/g.
  • 12. The method according to claim 5, wherein when the ratio is between 1% and 5%, identifying the raw material as inducing no mortality;when the ratio is between 5% and 15%, identifying the raw material as inducing low mortality;when the ratio is between 15% and 25%, identifying the raw material as inducing medium-high mortality; andwhen the ratio is greater than 25%, identifying the raw material as inducing acute mortality.
  • 13. The method according to claim 6, wherein the at least one probiotic bacterial strain comprises Lactobacillus acidophilus LA 02 LMG P-21381 deposited by the company Anidral Srl on Jan. 13, 2002, and Bifidobacterium animalis subsp. Lactis BS01 LMG P-21384 deposited by the company Anidral Srl on Jan. 13, 2002.
Priority Claims (1)
Number Date Country Kind
MI2013A001280 Jul 2013 IT national
PCT Information
Filing Document Filing Date Country Kind
PCT/IB2014/001416 7/30/2014 WO 00